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Summary
Interleukin 5 (IL5) acts on eosinophil differentiation and activation, suggesting the existence
of a membrane receptor for IL5 on eosinophils. Here, we report that 1251-labeled recombinant
human 11,5 bound, at 4°C, to high affinity receptors on human eosinophils. The association
constant was higher for hypodense eosinophils (1.93 x 109 M-1) than for normodense cells
(0.39 x 109 M -1), with a closely related number of receptor sites per cell. No specific binding
occurred on neutrophils. The specific binding of 1165 was induced by overnight incubation at
37°C of human eosinophils with granulocyte/macrophage (GM)-CSF. The levels of increase were
significantly higher for normodense than for hypodense eosinophils, suggesting a previous in
vivo activationof the later subpopulation by GM-CSF 1173 was ineffective by itselfbut synergistically
enhanced the effect of GM-CSF. Specificity studies showed that the binding of 1251-labeled IL5
was inhibited by 116, but not by other cytokines, on human eosinophils. These results show
the existence of a specific binding site for IL5 on human eosinophils with a variable affinity
on eosinophil hypodense or normodense subpopulations, as previously reported for other membrane
receptors.
T
he production and differentiation of eosinophils are
thought to be controlled by a group of hemopoietic
growth factors, namely, IL-3, granulocyte/macrophage CSF
(GM-CSF),' and IL-5 (1-3). However, 1175 appears to be
selective for the eosinophil lineage and stimulates the produc-
tion and maturation of eosinophils at terminal stages (1-3).
Human eosinophil heterogeneity is characterized by the ex-
istence during hypereosinophilic diseases of a subpopulation
of eosinophils called "hypodense" (4-7). Hypodense eo-
sinophils can be distinguished by an impaired oxidative me-
tabolism (6) and by an increased cytotoxic potential against
parasitic targets in vitro (7). Moreover, these cells exhibit an
increased expression of various membrane receptors (5, 7, 8)
besides a variability in protein expression (9). The presence
of hypodense eosinophils inhypereosinophilic situations can
therefore be related to eosinophils in a state of activation,
in addition to increased eosinophilopoiesis. IL5 might repre-
sent the majorcytokine involved in the induction ofhypodense
eosinophils and therefore in eosinophil-mediated pathology
'Abbreviations used in this paper . CR3, complement receptor type 3; GM-
CSF, granulocyte/macropbage colony stimulating factor; K,, association
constant; rh, recombinant human.
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(4). Similarly to other lymphokines, the biological effects of
IL5 are probably linked to the interaction with specific
receptors on susceptible targets. However, despite numerous
studies on IL5, nothing is known about the binding capacity
of IL5 to human eosinophils. The aim of the present study
was to demonstrate the existence of a specific receptor for
recombinant human (rh) IL5 on human eosinophils and to
investigate the variation of its expression in relation to eosin-
ophil heterogeneity. The effects of IL-3 and GM-CSF were
evaluated on IL5-specific binding to human eosinophils.
Materials and Methods
Reagents.
￿
Purified rb 11,5 was obtained as described elsewhere
(10). rh 11,3 and rh GM-CSF were generous gifts from Sandoz,
Ltd. (Basel, Switzerland) and Dr. R. L. Coffman (DNAX Insti-
tute, Palo Alto, CA), respectively. rh IFN-.y was provided by
Roussel-Uclaf (Romainville, France).
Purification ofEosinophih
￿
Humaneosinophils were purified from
the venous blood ofpatients with hypereosinophilia bycentrifuga-
tion upon discontinuous 18-25% (wt/vol) metrizamide gradients
(Nyegaard Co., Oslo, Norway) according to the technique previ-
ously described (6, 7). Several cell fractions containing >85% pure
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gradients. Eosinophils obtained in the lower density layers corre-
sponding to 20-22% metrizamide were referred to as hypodense
eosinophils. Eosinophils collected from the 23-25% metrizamide
layers were referred to as normodense eosinophils (6, 7). Neutro-
philspurified from normal volunteersby centrifugation on metriza-
mide gradients were always >95% pure, with no contaminating
eosinophils.
Cell Culture Conditions.
￿
Freshly isolated eosinophils in RPMI
1640 supplemented with 10% FCS and antibiotics were incubated
in the presence or absence of rh GM-CSF (5 x 10-'o M) and/or
rh 11,3 (2 x 10 -10 M) overnight at 370C in 5% C02. After over-
night incubation, eosinophils were used for IM binding assay, in
comparison with freshly isolated human eosinophils.
Radiolabeling ofrh IL5.
￿
rh IL5 was radiolabeledby the Iodogen
(Pierce Chemical Co., Rockford, IL) method yielding to a high
specific activity with little to no reduction in biological activity,
as previously described (11). Briefly, 2 ug of rh IL5 dissolved in
20 ul PBS was added to a microfuge tube coated with 5 jug of
dried Iodogen and containing 10 Ag of PBS with 500 uCi 125I-
Na (Amersham International, Amersham, UK). The mixture was
incubated at 40C for 20 min. Radiolabeled rh 11,5 was separated
from excess 1251 by using a gel filtration column (model PD-10;
Pharmacia Fine Chemicals, Piscataway, NJ). The average specific
radioactivity was 1.82 t 0.41 x 10'5 cpm/mmol.
Binding Assay for '24-labeled rh 11,5.
￿
The binding of 1251-labeled
rh IM was measured according to the method described previ-
ously (11, 12) with some modifications. Briefly, before addition of
various concentrations of 1251-IIr5, the cells (106 in 100 Al HBSS
with 0.35% BSA and 0.0025% cycloheximide) were incubated in
the presence or absence of a 100-fold excess of unlabeled rh IIr5
for 30 min at 4°C. After incubation, serial dilutions of radiola-
beled rh IL5 were added and the cells were incubated in microfuge
tubes at 4°C for 2 h. After washings, the cell suspensions were
centrifuged at 8,500 g for 2 min, through 1 ml of 20% sucrose,
and the radioactivity ofthe pellets was measured in a gamma counter
(LKB, Turku, Finland). Each experiment was performed in dupli-
cate or more. The specific binding was defined as the difference
between the total binding and the nonspecific binding obtained
in the presence ofa 100-fold molar excess ofunlabeled rh IM. The
association constant (K,) and the average number of binding sites
per cell were calculated by Scatchard analysis of the saturation
binding data.
Statistical Analysis.
￿
Data were expressed as mean ± SE. Stu-
dent's t test was used for comparison of means, a P value of 0.05
or less being considered significant.
Results
Binding Characteristics ofIL5 on Eosinophils.
￿
A saturation
binding experiment with eosinophils using 106 cells per
point was performed at 4OC for 2 h in the presence of in-
creasing concentrations of 1251-IL5. As shown in Fig. 1, 1251-
11,5 specifically bound to human eosinophils and reached satu-
ration at an approximate concentration of 1.0 or 1.25 nM.
In this representative experiment, the specific binding of rh
IL5 to normodense and to hypodense eosinophils obtained
from the same patient was compared. Scatchard plot analysis
of the binding data revealed the presence of 600 receptors
per cell with an apparent K, of 1.0 x 109 M -1 on hypo-
dense eosinophils and 490 receptors per cell with a K, of 3.7
x 108 M -1 on normodense eosinophils (Fig. 1, inset). To
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Figure 1.
￿
Specific equilibrium binding curve of 1251-IL5 to human eo-
sinophils. Hypodense eosinophils (0) and normodense eosinophils (M),
obtained from the same donor, were incubated with various concentra-
tions of 1251-IL5 for 2 h at 4°C. The specific binding was determined after
subtraction of nonspecific binding and the data were reexpressed as a
Scatchard plot analysis (inset). Each pointrepresents the mean ofduplicate
determinations.
further investigate the variable expression ofMR. on human
eosinophils, comparative studies of IL5 binding to hypodense
and normodense eosinophils were performed. The results
showed that hypodense eosinophils (n = 9) have 446 ± 97
I1r5Rs per cells, with a K, of 1.93 ± 0.4 x 109 M-1, while
normodense eosinophils (n = 5) had 460 ± 89 IL5Rs per
cell with a K, of 3.91 ± 0.43 x 108 M-1. The K, of the
IIr5Rin the case ofhypodense eosinophils was fivefold greater
than with normodense eosinophils, whereas the number of
receptors per cell was not different between the two subpopu-
lations.
The binding ofrh IL5 was evaluated on neutrophils. No
significant difference between total and nonspecific binding
was observed, indicating that specific IL5Rs were not de-
tectable on human neutrophils (data not shown) .
Induction ofIL5R on Human Eosinophils.
￿
To further in-
vestigate the mechanisms involved in the heterogeneous ex-
pression of IL5R, human eosinophils were cultured over-
night in the presence or absence of GM-CSF or IL3 before
the IM binding assay. Results shown in Fig. 2 indicated that
IL5 binding to hypodense eosinophils could be modulated
afterin vitro incubation with GM-CSF. Whereas eosinophils
cultured without GM-CSF expressed a low specific IL-5
binding, the specific 11,5 binding was increased when the
same eosinophils had been cultured with GM-CSF. The
Scatchard analysis revealed in the later case the existence of
550 receptors per cell with a K, of 2.87 x 109 M -1 (Fig.0
E
u>
J
V
C
O
02
70 ~
20
10
0
0
￿
10
￿
20
￿
0~0
￿
40
￿
5~0
￿
6~0
Bound IL-5 (mo1ecu1eWce11)X10i
GM-CSF (+)
IL-5 added (nM)
GM-CSF (-)y(+)
GM-CSF (-)
0,0
￿
0,5
￿
1 .0
￿
1 .5
Figure 2. Specific 1251-IL5 binding to human eosinophils, cultured
without GM-CSF (0) or with GM-CSF (0) overnight at 37°Cbefore
incubation with increasing concentrations of 1251-IL5 for 2 h at 4°C. In
addition, after culture without GM-CSF, eosinophils were cultured over-
night with GM-CSF and submitted to the 1251-IL5 binding assay (").
Specific equilibrium binding was determinedafter subtractionof nonspecific
binding and the data were reexpressed as a Scatchard plot analysis (inset).
Each point represents the mean ofduplicate determinations. In this study,
hypodense eosinophils were used.
2, inset). In addition, when human eosinophils first cultured
without GM-CSF were then cultured with GM-CSF over-
night, a specific binding of 11,5 was now expressed. The
Scatchard analysis revealed the existence of 210 receptors per
cell with a K, of 3.2 x 109 M-1 (Fig. 2, inset). In the same
conditions, human eosinophils cultured with IL-3 did not
specifically bind 11,5 similarly to eosinophils cultured without
lymphokines (data not shown). To extend these findings, the
specific IL-5 binding was evaluated on normodense and
hypodense eosinophils cultured overnight in the presence or
absence of GM-CSF before incubation with 1251-IL5 (Fig.
3 A). As previously shown, in the case of freshly isolated
eosinophils (precultureconditions), the specific IL-5 binding
was greater on hypodense than on normodense eosinophils.
After culturewithout GM-CSF (medium alone), the specific
IL-5 binding was still detected on hypodense eosinophils, but
not on normodense eosinophils. However, cultivation with
GM-CSF induced 116-specific binding both on hypodense
or normodense eosinophils. It can be also noticed on Fig.
3 A that the increasing effects of GM-CSF, when compared
with precultured eosinophils, were significantly higher in the
case of normodense than in the case of hypodense eosinophils.
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Figure 3.
￿
(A) Effect of GM-CSF on specific 11,5 binding to human
eosinophils. Human eosinophils, freshly isolated (preculture), or cultured
overnight without GM-CSF (medium alone) or with GM-CSF, were in-
cubated with 0.5 nM of 1251-11,5 for 2 h at 4°C. Specific IIT5 binding
to hypodense eosinophils (®, n = 9) or normodense eosinophils (0, n
5) was determined after subtraction of nonspecific binding. Data are
expressed as mean ± SE. (B) The effect of IL3 alone, or IL3 + GM-CSF
on specific 11,5 binding to human eosinophils (four experiments with
hypodense eosinophils and one experimentwith normodense eosinophils).
Human eosinophils, cultured with 11,3, or with IL3 + GM-CSF, were
incubated with the same concentration of 1251-11,5 (0.5 nM) for 2 h at
4°C. Data are expressed as mean ± SE of five independent experiments.
Results presented in Fig. 3 B revealed that IL3 could not
by itself induce the specific binding of 11,5. However, when
eosinophils were cultured with GM-CSF and IL3 together
an increase in the specific IL-5 binding to eosinophils was
detected, suggesting a synergistic effect between IL-3 and
GM-CSF.
Specificity of11,5 Binding to Human Eosinophils.
￿
To deter-
mine whether the binding of IL5 to human eosinophils was
specific for IM, competition binding experiments with other
lymphokines showing amino acid sequence homology with
IL5 in short segments were performed. None of the lym-
phokines tested -IL3 (5 x 10-6 M), GM-CSF (5 x 10 -6
M), and IFN-y (1 x 10 -6 M)-showed any significant
effect on the binding of 1251-IL5 to human eosinophils (data
not shown).
Discussion
IL5 plays a major role in the production, differentiation,
and activation of eosinophils as well as B lymphocytes (12).
The pleiotropic effects of IM on hematopoietic cells are prob-
ably linked to the expression of specific receptors on suscep-
tible target cells. However, despite the well-known biolog-
ical effects of IL5, there is no report on a specific binding
site for IL5 on eosinophils, while a recent study described
an ILSR on a murine B cell line (12) . In the present paper,1211-labeled rh IL5 was used to demonstrate the existence
and to examine the level of expression of a receptor for 11,5
on human eosinophils. The results presented here show that
11,5 specifically interacts on the surface of eosinophils but
not on neutrophils, a finding that correlates with the lack
of effect of 11,5 on the neutrophil myeloid series. The present
results indicate that the binding of 11,5 was to a single class
affinity receptor. This is similar to receptors for 11,3 or GM-
CSF on human eosinophils (13), but different from the receptor
for IL -5 described on the murine B cell line BCL1-B20 (12).
From the Scatchard plot analyses, IL5R expression was
different on hypodense and normodense eosinophils. 11,5
bound to hypodense eosinophils with a fivefold higher K,
than for normodense eosinophils, a result that suggests the
previous in vivo activation of hypodense eosinophils. In con-
trast, the number of receptor sites per cell was not different
between the two eosinophil cell populations, and was con-
sistent with the small number ofhigh affinity receptors for
other lymphokines (IL3 and GM-CSF) recently described on
eosinophils (13). After an overnight incubation ofeosinophils
at 37°C, in the absence of added cytokines, a specific binding
of labeled 11,5 was still detected on hypodense eosinophils
but not on normodense populations. These results might in-
dicate that the loss o£ binding capacity of IL5 was slower
for hypodense than for normodenseeosinophils. This is con-
sistent with the fact that hypodense eosinophils have a
prolonged life span in vivo and ex vivo without lymphokines
(4, 5) . Our results on IL5 binding to hypodense and nor-
modense eosinophils further illustrate the heterogeneity of
these two populations already demonstrated for the expres-
sion of low-affinity IgE receptors and IgE-mediated cytotoxic
function, and the expression ofCR3 (7, 8) as well as protein
profiles (9). These similarities suggest that the biological
changes in hypodense eosinophils might be under the influence
of the same factors. In fact, in a different study related to
the induction of various surface markers on eosinophils, we
could recently show that the expression of CD23, CD11b
(CR3), and CD4 was closely related to the effect of eo-
sinophilopoietic growth factors such as 11,5 (Chihara, J., V
Gruart, J. Plumas, A. Capron, and M. Capron, manuscript
in preparation).
In the context ofthevariable expression of IL5Rs on human
eosinophils, it was interesting to investigate the effects ofeo-
sinophilopoietic growth factors such as GM-CSF and IIs3
on the specific IL5 binding. The present results indicate that
an overnight culture with GM-CSF could increase the ex-
pression of IL5R not only on hypodense, but also on nor-
modense eosinophils. The level of increase of IL5 binding
after induction by GM-CSF was inferior for hypodense than
for normodense eosinophils, suggesting that hypodense eo-
sinophils might have been exposed to an excess of GM-CSF
in vivo, and might be deactivated upon further exposure. The
enhancing effects of GM-CSF on IL5 binding to human eo-
sinophils are consistent with the ability of this factor to stimu-
late eosinophil colonies invitro. Indeed, eosinophil colonies
are selectively induced by 116, but further enhanced after
the addition of GM-CSF or IL3 (1, 3). In fact, IL-3 alone
could not induce IL5 binding to human eosinophils. How-
ever, in synergy with GM-CSF, IL3 could increase 11,5 binding
to human eosinophils. These findings are not in total agree-
ment with a recent study showing a reciprocal inhibition of
binding to human eosinophils between IL-3 and GM-CSF
and suggesting common biological effects (13). In our studies,
the binding or radiolabeled 11,5 to eosinophils was found to
be inhibited only by unlabeled 11,5 and not by 11,3, GM-
CSF, IFN-y suggesting the specificity of the binding site for
IL5 on humaneosinophils. The characteristics of IL-5 binding
to human eosinophils and to murine B cells are not totally
identical, especially with respect to the presence of a single
class affinity receptor for eosinophils, whereas high- and low-
affinity receptors are detected on B cell lines (12). Further-
more, mAbs to mouse B cell IL5Rs did not bind to human
eosinophils (data not shown). Because ofthe limited amount
of eosinophils from human patients, only preliminary cross-
linking studies have been performed. They suggest that the
IL5R on human eosinophils has an approximate molecular
weight of50,000. The molecular relationships between the
IL5R on eosinophils and on B lymphocytes await further
investigation.
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